Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

The S&P 500 advanced 1% on Monday, June 23, 2025, as investors weighed the potential severity and impact of Iran's ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

--On pace for largest percent decrease since Nov. 12, 2024, when it fell 7.14% --Currently down four consecutive days; down 8% over this period --Longest losing streak since May 6, 2025, when it fell ...